Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.
Mercredi, H.C. Wainwright a maintenu sa notation Neutre sur Geron Corporation (NASDAQ: GERN) suite à l’approbation récente de son médicament Rytelo par la Commission européenne. Selon les données d’ I ...
Analysts' ratings for Geron (NASDAQ:GERN) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table provides a quick overview of their recent ratings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback